BALTIMORE, MD--(Marketwired - May 8, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the market for the Nuvilex, Inc. (
The Company's live-cell encapsulation drug delivery platform has already demonstrated that it can significantly improve the efficacy and safety results in mid-stage clinical trial studies in patients in advanced stages of pancreatic cancer. Given the ability of the platform to activate pro-drugs and maintain a high degree of safety, management believes that the platform can be used to treat multiple forms of cancer, as evidenced in preclinical studies. Therefore, as the development progresses, it is not inconceivable that the size of the market for platform reaches the tens of billions worldwide.
Since great promise has been demonstrated in its preclinical breast cancer studies, it is possible that trials to treat the $10 billion breast cancer market are next on Nuvilex's list.
Each year, 230,000 women in the U.S. are diagnosed with breast cancer. Interestingly, some of the FDA-approved treatments for breast cancer are being studied now to treat pancreatic cancer. However, to date, some of these treatments have demonstrated lower efficacy and survival rates in pancreatic cancer patients than with breast cancer patients.
Treatments that employ Nuvilex's cell encapsulation technology have demonstrated strong efficacy in mid-stage clinical trials in advanced pancreatic cancer. Therefore, it is possible that the results with breast cancer could ultimately show that the cell encapsulation technology can also be substantially positive, and perhaps even more so, for this indication than they are for pancreatic cancer.
Finally, since the Nuvilex (
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (